Category: News & Comments
Advaxis: Why This Small Firm's Stock Outperformed on a Negative Market Day
Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ ( ADXS ) stock rallied today as the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on its product AIM2CERV ( axalimogene filolisbac ). The product is in...
Read More
May 15, 2019
0
Why Do We Like Mannkind Now?
On November 2, 2017 Mannkind (MNKD) announced that the FDA has approved an update to its inhaled insulin product Afrezza prescribing information to include new clinical data that were presented at the American Diabetes Association's 76th Scientific Sessions in June...
Read More
October 5, 2017
0
Observing Array Biopharma
A number of biotech or biopharmaceutical companies have succeeded in the past couple of years in changing their statuses from clinical stage to revenues-generating firms. A number of these firms reside in the Prohost Portfolio , picked up before they...
Read More
October 31, 2018
0
Vertex: Good News and Good Decisions
Vertex's Good News Vertex and Kymera Therapeutics Collaboration Last week Vertex Pharmaceuticals ( VRTX ) and Kymera Therapeutics entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets . Kymera is...
Read More
May 23, 2019
0
KalVista Pharmaceuticals Signs a Lucrative Strategic Agreement with Merck
- The Agreement Covers the Development of Investigational Plasma Kallikrein Inhibitors for Diabetic Macular Edema (DME) - Upfront Fee ($37 Million). Potential Milestone Payments. Royalties On Sales. The deal could be worth $750 million - Merck Acquires 9.9% Stake in KalVista in...
Read More
October 11, 2017
0
About Illumina's acquisition
Illumina (ILMN) and Pacific Biosciences (PACB) announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share, in an all-cash transaction. The agreement has already been approved by the board of directors of both...
Read More
November 2, 2018
0
RegenxBio: Another licensing agreement providing additional validation of its NAV platform
RegenxBio (RGNX) has granted Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject to certain non-exclusive rights previously granted for MPS IIIA) for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA) and type B...
Read More
November 5, 2018
0
Exelixis: A Day for Celebrating and Learning
Two game changing news has come together on October 16, 2017, both indicating that Exelixis (EXEL) is on its way to reach its goal becoming the leader in the current oncology discovery and development field. THE FIRST GOOD...
Read More
October 17, 2017
0
Cara Therapeutics: More Positive Results from the Korsuva Product Trial for Hemodialysis Patients' Pruritis
Positive Results from Korsuva for Pruritis Cara Therapeutics Postive Results from Korsuva Trial On May 29, 2019 Cara Therapeutics ( CARA ) announced positive topline data from the KALM-1 pivotal Phase 3 trial of its Korsuva in hemodialysis patients with...
Read More
May 30, 2019
0
Gilead's CAR T Drug, Yescarta, is Approved for NHL Resisting Previous Treatments
As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration (FDA) has given the green light to a second CART immuno-oncology product with the trade name Yescarta . This drug, which has been developed...
Read More
October 19, 2017
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)